Inhibition of FcγRIIA-dependent platelet aggregation by dasatinib according to CD148 Q276P/R326Q polymorphisms. Platelets from 10 healthy donors were treated with increasing concentrations of dasatinib (0, 20, 40, 60, 80, and 100nM) before induction of aggregation by ALB6 (2.5 μg/mL). Aggregation curves (A-B) are representative of results obtained with platelets from noncarriers (A) and carriers of the CD148 276P/326Q isoforms (B). The mean increase in lag time (± SEM) in the presence of dasatinib was compared (t test) between noncarriers (n = 6, ▩) and carriers of the CD148 276P/326Q isoforms (n = 4, ▨).